EML4-ALK variant 3 + TP53 mutation
|
LUAD
|
EML4-ALK variant 3 + TP53 mutation
|
LUAD
|
alectinib Resistant: C4 – Case Studies
|
alectinib Resistant: C4 – Case Studies
|
EML4-ALK variant 3 + TP53 mutation
|
LUAD
|
EML4-ALK variant 3 + TP53 mutation
|
LUAD
|
brigatinib Resistant: C4 – Case Studies
|
brigatinib Resistant: C4 – Case Studies
|
EML4-ALK variant 3 + TP53 mutation
|
LUAD
|
EML4-ALK variant 3 + TP53 mutation
|
LUAD
|
lorlatinib Resistant: D – Preclinical
|
lorlatinib Resistant: D – Preclinical
|
EML4-ALK variant 3 + TP53 mutation
|
LUAD
|
EML4-ALK variant 3 + TP53 mutation
|
LUAD
|
crizotinib Sensitive: D – Preclinical
|
crizotinib Sensitive: D – Preclinical
|